Ga-68 Production Methods in Modern Nuclear Medicine

2026-03-11

Growing Clinical Importance of Ga-68

Gallium-68 (Ga-68) has become an increasingly important radionuclide in PET molecular imaging. With a half-life of approximately 67.7 minutes, Ga-68 can be used to label a variety of targeting molecules and peptides, enabling highly specific imaging of tumors.

The clinical adoption of Ga-68 accelerated after several Ga-68 radiopharmaceuticals received regulatory approval. In 2016, the U.S. FDA approved ⁶⁸Ga-DOTATATE for imaging neuroendocrine tumors, and in 2020 approved ⁶⁸Ga-PSMA-11 for prostate cancer imaging.

These approvals significantly expanded the clinical role of Ga-68 in oncology and stimulated rapid growth in demand for Ga-68 radiotracers worldwide.

Ga-68 Production Methods

Today, Ga-68 can be produced through three main approaches: generator systems, cyclotron liquid target production, and cyclotron solid target production.

Each method has different advantages in terms of infrastructure requirements, production capacity, and operational cost.

Generator-Based Production

The most widely used source of Ga-68 in clinical practice is the ⁶⁸Ge/⁶⁸Ga generator. In this system, Ga-68 is obtained through the radioactive decay of the parent isotope Ge-68 and can be eluted directly for radiopharmaceutical labeling.

Generator systems are attractive because they are simple to operate and require minimal infrastructure. However, generator-based production also has several limitations. The activity obtained from each elution is relatively limited, and the performance of the generator gradually decreases over time as the parent isotope decays. In addition, generators typically need to be replaced every 9–12 months, which contributes to relatively high long-term operational costs.

Cyclotron Liquid Target Production

Cyclotron-based liquid target production is another approach for producing Ga-68. Compared with generator-based production, liquid target systems can provide higher activity output and greater flexibility in production scheduling. The process can also be integrated with automated chemical separation and synthesis systems https://www.chinacyclotron.com/isotopex-lab-product/, allowing radionuclide production to be incorporated into existing radiopharmaceutical workflows.

At the same time, this approach relies on cyclotron infrastructure and dedicated target systems, and typically involves radiochemical processing steps to obtain purified Ga-68 suitable for radiopharmaceutical labeling. Operational factors such as target material consumption and system configuration are also part of routine production considerations.

For these reasons, liquid target production is commonly implemented in facilities that already operate cyclotrons and require higher radionuclide output than generator systems can provide.

Cyclotron Solid Target Production

Another important approach for Ga-68 production is cyclotron irradiation using solid targets. In this method, proton beams irradiate solid target materials, followed by chemical processing to obtain purified radionuclides suitable for radiopharmaceutical applications.

Compared with generator-based systems, solid target production can provide significantly higher activity output and lower operational cost over time, making it suitable for facilities that require larger radionuclide quantities.

Because of these characteristics, solid target systems are commonly implemented in centralized radionuclide production centers, where isotopes can be produced in larger batches and distributed to multiple medical institutions.

LBT'S LB-11 MTS and LB-20 Medical Cyclotron Platform

LB-11 MTS and LB-20 medical cyclotrons provide flexible platforms for radionuclide production in modern nuclear medicine facilities, supporting both liquid and solid target configurations. For Ga-68 production, the systems can be configured with liquid targets as an alternative to generator-based production, while solid target configurations enable higher-yield Ga-68 production.

Beyond Ga-68 production, these cyclotron platforms can also support the routine production of commonly used PET radionuclides such as ¹⁸F, ¹¹C, and ¹³N, and—when equipped with solid target systems—can enable the production of metallic radionuclides including ⁶⁴Cu and ⁸⁹Zr, supporting both clinical imaging and research applications in nuclear medicine.